CEO David DeStefano highlighted Vertex's strong start to 2025, reporting $177.1 million in revenue, a 12.9% year-over-year increase, supported by 14.4% growth in subscription revenue and 29.6% growth ...

BMO Capital Markets analyst Daniel Jester reiterated the Market Perform rating on Vertex, Inc. (NASDAQ:VERX), raising the price target to $28 from $24. Investors rewarded the consistent execution ...

Vertex Pharmaceuticals Incorporated (VRTX) is a good speculative biotech play to look into. That's because it is doing well in the Cystic Fibrosis [CF] space. It will still continue to do well with ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

AI is a core focus for Google, and at its Google Next event today, the company announced a series of updates across its portfolio that benefit from the power of generative AI. Front and center are ...

Vertex Pharmaceuticals (VRTX) delivered strong third-quarter results for 2025, surpassing analysts’ expectations with an earnings per share (EPS) of $4.80 against a forecast of $4.57, marking a 5.03% ...

Companies perform stock splits for a variety of reasons, from a desire to increase the liquidity of their shares to an interest in making them more accessible to a wider range of investors. Such ...

Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets ...

It's on track to launch more blockbuster drugs. Companies perform stock splits for a variety of reasons, from a desire to increase the liquidity of their shares to an interest in making them more ...